Adverse reactions and symptomatic treatment of immunological checkpoint inhibitors in tumor therapy

VernacularTitle:免疫检查点抑制剂在肿瘤治疗中的不良反应及对症治疗
Author: Li'na ZHOU ¹ ; Hongmei LI
Author Information

1. 266000,青岛大学附属医院肿瘤化疗科
Keywords: Neoplasms; Immunological checkpoint inhibitors
From: Journal of International Oncology 2017;44(11):860-863
CountryChina
Language:Chinese
Abstract: Immunological checkpoint inhibitors include monoclonal antibodies of cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1).Anti-CTLA-4 drug ezetimab (ipilimumab)and anti-PD-1 drug (pembrolizumab and nivolumab) are approved for the treatment of melanoma and non-small cell lung cancer.The effects of these drugs on renal cell carcinoma,bladder cancer,breast cancer,gastrointestinal cancer and other types of cancers are still in large-scale clinical trials.These drugs have good effects in the clinical application,but they inevitably lead to many adverse reactions.